Jeyaraman N, Jeyaraman M, Ramasubramanian S, Balaji S, Muthu S. Beyond statistical significance: Embracing minimal clinically important difference for better patient care. World J Methodol 2025; 15(1): 97814 [DOI: 10.5662/wjm.v15.i1.97814]
Corresponding Author of This Article
Madhan Jeyaraman, MS, PhD, Assistant Professor, Research Associate, Department of Orthopaedics, ACS Medical College and Hospital, Dr MGR Educational and Research Institute, Velappanchavadi, Chennai 600077, Tamil Nadu, India. madhanjeyaraman@gmail.com
Research Domain of This Article
Orthopedics
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Naveen Jeyaraman, Madhan Jeyaraman, Department of Orthopaedics, ACS Medical College and Hospital, Dr MGR Educational and Research Institute, Chennai 600077, Tamil Nadu, India
Naveen Jeyaraman, Madhan Jeyaraman, Sathish Muthu, Department of Research Methods, Orthopaedic Research Group, Coimbatore 641045, Tamil Nadu, India
Swaminathan Ramasubramanian, Sangeetha Balaji, Department of Orthopaedics, Government Medical College, Omandurar Government Estate, Chennai 600002, Tamil Nadu, India
Sathish Muthu, Department of Biotechnology, Faculty of Engineering, Karpagam Academy of Higher Education, Coimbatore 641021, Tamil Nadu, India
Sathish Muthu, Department of Orthopaedics, Government Medical College, Karur 639004, Tamil Nadu, India
Author contributions: Jeyaraman M conceptualized the manuscript; Jeyaraman N, Ramasubramanian S, and Balaji S performed data analysis and wrote the manuscript; Muthu S performed image analysis. All authors have read and approved the final version of the manuscript.
Conflict-of-interest statement: All authors declare no conflict of interest in publishing this manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Madhan Jeyaraman, MS, PhD, Assistant Professor, Research Associate, Department of Orthopaedics, ACS Medical College and Hospital, Dr MGR Educational and Research Institute, Velappanchavadi, Chennai 600077, Tamil Nadu, India. madhanjeyaraman@gmail.com
Received: June 9, 2024 Revised: September 9, 2024 Accepted: September 13, 2024 Published online: March 20, 2025 Processing time: 111 Days and 18.4 Hours
Abstract
The minimal clinically important difference (MCID) represents a pivotal metric in bridging the gap between statistical significance and clinical relevance, addressing the direct impact of medical interventions from the patient's perspective. This comprehensive review analyzes the evolution, applications, and challenges of MCID across medical specialties, emphasizing its necessity in ensuring that clinical outcomes not only demonstrate statistical significance but also offer genuine clinical utility that aligns with patient expectations and needs. We discuss the evolution of MCID since its inception in the 1980s, its current applications across various medical specialties, and the methodologies used in its calculation, highlighting both anchor-based and distribution-based approaches. Furthermore, the paper delves into the challenges associated with the application of MCID, such as methodological variability and the interpretation difficulties that arise in clinical settings. Recommendations for the future include standardizing MCID calculation methods, enhancing patient involvement in setting MCID thresholds, and extending research to incorporate diverse global perspectives. These steps are critical to refining the role of MCID in patient-centered healthcare, addressing existing gaps in methodology and interpretation, and ensuring that medical interventions lead to significant, patient-perceived improvements.
Core Tip: The minimal clinically important difference (MCID) is crucial for assessing the real-world impact of medical treatments from a patient’s viewpoint. It ensures clinical outcomes are both statistically significant and beneficial in practice. Future directions involve standardizing MCID methods, increasing patient participation in setting thresholds, and broadening research for global applicability, enhancing MCID’s role in delivering meaningful, patient-valued healthcare outcomes.
Citation: Jeyaraman N, Jeyaraman M, Ramasubramanian S, Balaji S, Muthu S. Beyond statistical significance: Embracing minimal clinically important difference for better patient care. World J Methodol 2025; 15(1): 97814
The minimal clinically important difference (MCID) stands as a crucial metric in clinical research and patient care, distinguishing between statistical significance and clinical meaningfulness[1-3]. Unlike statistical significance, which validates an effect's non-randomness, MCID identifies the smallest change in a treatment outcome that patients perceive as beneficial or detrimental. This distinction is critical in ensuring that the metrics used to assess medical success resonate with patient priorities and real-world implications. In the dynamic landscape of modern healthcare, where evidence-based practices dictate treatment modalities, the concept of MCID has emerged as a beacon for navigating the complex interplay between statistical significance and clinical relevance[4,5]. It represents the smallest change in a treatment outcome that a patient perceives as beneficial, thereby gaining significance from a clinical standpoint. This threshold not only aids in assessing the efficacy of interventions but also helps in understanding their practical implications for patient care.
One might ask, "Is statistical significance sufficient to dictate clinical decisions?" This question strikes at the core of contemporary medical practice debates, challenging the reliance on p-values and statistical metrics as the sole arbiters of therapeutic success. MCID's significance becomes evident when considering a new drug that, despite showing statistically significant improvements in clinical trials, only marginally affects the patient's quality of life or symptoms. Such scenarios raise important questions about the true effectiveness of medical interventions in practical terms. By incorporating MCID, clinicians and researchers can ensure that clinical outcomes are not only statistically significant but also genuinely relevant to patients[6,7]. This approach aligns healthcare strategies with patient expectations and needs, ultimately enhancing the quality of patient care. The primary objectives of this review are to: (1) Explore how MCID refines the interpretation of clinical trial results and influences healthcare policies; (2) Analyze the current challenges in MCID application across various medical specialties; and (3) Propose standardized approaches and future directions for enhancing MCID's role in patient-centered care. This comprehensive analysis aims to provide a unified framework for MCID application that addresses existing gaps in methodology and interpretation.
UNDERSTANDING MCID
MCID is a crucial metric in medical research and clinical practice, representing the smallest difference in score in the outcome of interest that patients perceive as beneficial or harmful[8,9]. Unlike statistical significance, which tests the probability that a result is due to chance rather than a specific intervention, MCID addresses the magnitude of change that must be achieved to be meaningful from a patient's perspective[1,10]. This differentiation is fundamental, as statistically significant results can sometimes be clinically irrelevant, especially when the detected changes are too minor to impact patients' quality of life. The concept of MCID was first introduced in the 1980s by Jaeschke, Singer, and Guyatt as a systematic approach to determine whether a clinical effect is large enough to matter to patients[11]. This came about as a response to the growing concern that the statistical measures commonly used in clinical trials often failed to capture outcomes that were important from a patient's standpoint[1]. Initially developed in the context of chronic lung disease, MCID has since evolved and expanded across various fields of medicine as a means to bridge the gap between statistical analysis and clinical relevance[12,13].
To illustrate the practicality of MCID and the gap between statistical significance and clinical relevance, consider a study on pain management in osteoarthritis patients. In a clinical trial of a new analgesic, researchers found a statistically significant reduction in pain scores (P < 0.001) compared to placebo. However, the average pain reduction was only 0.5 points on a 10-point scale. While statistically significant, this change falls below the established MCID of 1.0 point for osteoarthritis pain scales[14]. This example highlights how MCID provides crucial context: Despite achieving statistical significance, the treatment may not offer meaningful benefits to patients in their daily lives. The adoption of MCID has been driven by a broader shift in healthcare towards patient-centered care, where the impacts of treatments are evaluated not just by physiological or biochemical markers, but also by their actual effects on patients' lives[15]. Over the decades, researchers have worked to refine the methods for calculating MCID, incorporating both anchor-based and distribution-based approaches to cater to different clinical conditions and outcomes. Today, MCID is applied across a diverse range of medical specialties, each adapting the concept to their specific clinical needs and patient outcomes (Table 1).
Table 1 Applications of minimal clinically important difference in various medical specialties.
Specialty
Application of MCID
Key outcome measures
Example of impact
Orthopedics
Evaluation of surgical outcomes (knee/hip replacements)
Pain reduction; mobility enhancement
Determines the significance of improvements in joint function
Oncology
Assessing treatment impact on quality of life
Symptoms management; Side effect severity
Helps in managing therapy options considering patient perceptions of change
Neurology
Effectiveness in treatment of chronic neurological diseases
Disease progression; Motor function
Utilized in assessing therapies in conditions like multiple sclerosis
Psychiatry
Efficacy of treatments for mood disorders
Changes in psychiatric rating scales
Crucial for interpreting clinically meaningful changes in mental health
Pulmonology/Cardiology
Patient-reported outcomes for respiratory and heart diseases
Breathlessness; Exercise capacity
Assists in evaluating interventions impacting daily activities
Physical therapy and rehabilitation
Setting goals and measuring progress in recovery
Pain reduction; Functional recovery
Guides clinicians in tailoring rehabilitation programs
Orthopaedics
In orthopaedic research, MCID is extensively used to evaluate the effectiveness of surgeries like total knee or hip replacements. Here, MCID helps in determining the degree of pain reduction or mobility enhancement that patients find worthwhile. For instance, studies on osteoarthritis patients undergoing joint replacement surgery use MCID to assess improvements in joint function and pain relief, which are critical for patients' quality of life and long-term recovery[16,17].
Oncology
In the field of oncology, MCID is crucial for assessing the impact of treatments on symptoms, side effects, and overall life quality. Cancer treatments can have severe side effects, and understanding what constitutes a meaningful improvement or deterioration is vital for managing therapy options. MCID calculations are used to gauge patient perceptions of changes in pain, fatigue, and nausea, which are common during chemotherapy and radiation therapy[18,19].
Neurology
Neurologists apply MCID to evaluate the effectiveness of treatments for conditions like multiple sclerosis, Parkinson’s disease, and neuropathic pain. In these conditions, small improvements can make significant differences in patient autonomy and daily functioning. For example, the MCID for the Expanded Disability Status Scale in multiple sclerosis research helps determine the effectiveness of disease-modifying therapies in halting disease progression or improving motor functions[9,20].
Psychiatry
In psychiatry, MCID is used to measure the efficacy of treatments for depression, anxiety, and other mood disorders. It is essential for determining the clinical relevance of changes observed in psychiatric rating scales, such as the Hamilton Depression Rating Scale, where an MCID provides a clearer indication of whether a treatment has produced a change that is meaningful to the patient[21,22].
Pulmonology and cardiology
MCID also finds applications in pulmonology and cardiology, particularly in assessing patient-reported outcomes for interventions targeting asthma, COPD, and heart failure. In these specialties, MCID helps in evaluating the impact of treatments on patient-reported breathlessness, exercise capacity, and overall ability to engage in daily activities[23,24].
Physical therapy and rehabilitation
Physical therapists and rehabilitation specialists use MCID to set realistic goals and measure progress in terms of pain reduction, functional recovery, and improvement in life activities[25,26]. By understanding the MCID, clinicians can tailor rehabilitation programs to meet the specific improvements that are meaningful to patients recovering from injuries, surgeries, or chronic conditions.
Preventive medicine and public health
In preventive medicine, MCID is used to assess the effectiveness of interventions aimed at lifestyle changes, such as weight loss programs, smoking cessation, and exercise regimens[9,27,28]. Here, MCID helps determine the minimal changes in health parameters like body weight, cholesterol levels, or blood pressure that patients perceive as beneficial.
MCID has transformed the approach towards clinical trials and patient care by ensuring that the measures of effectiveness are directly relevant to patient experiences and expectations. This alignment not only enhances the credibility of clinical research but also ensures that healthcare practices are genuinely impactful, promoting treatments that deliver meaningful improvements in patient health and well-being.
IMPORTANCE OF MCID IN CLINICAL PRACTICE
In modern healthcare, patient-centered care is not just a buzzword but a critical operational principle guiding clinical practice. The concept of MCID plays a pivotal role in implementing this principle by providing a metric that gauges the smallest benefit of medical interventions that patients perceive as meaningful[28-30]. This threshold is essential not only for evaluating treatment effectiveness but also for tailoring treatments to individual patient needs and enhancing the quality of life. The integration of MCID into clinical practice fosters a deeper understanding of what patients consider valuable, guiding both treatment strategies and patient counseling. MCID supports the tailoring of treatments to meet individual patient preferences and expectations. In orthopedics, for example, the application of MCID in assessing postoperative outcomes such as pain and mobility allows clinicians to determine whether the changes experienced by patients meet or exceed the thresholds that patients themselves consider important[16]. This is crucial because what might be statistically significant in a clinical trial may not translate into meaningful or noticeable improvements in a patient's daily life. By focusing on MCID, healthcare providers can prioritize interventions that are likely to achieve outcomes that patients will notice and value, thus directly enhancing their quality of life. In the management of chronic conditions such as diabetes or hypertension, MCID helps in understanding the clinical significance of small changes in symptom management or disease markers[4]. For instance, in diabetes management, minor reductions in HbA1c might be statistically significant, but the MCID provides insight into how these changes affect patients' perceptions of their health and wellbeing, which in turn can influence their engagement with treatment and self-management strategies[17].
DECISION MAKING
MCID is invaluable in clinical decision-making, affecting everything from the choice of interventions to the design of treatment plans and patient counselling[4,28,31]. It provides a quantifiable measure that helps clinicians decide which treatments are worth pursuing based on their ability to produce changes that patients will perceive as beneficial. For example, in the field of pain management, determining the MCID for various interventions, such as pharmacologic therapies or physical therapy, enables clinicians to make informed decisions about which treatments to recommend based on the likelihood of achieving perceptible improvements for the patient[32-35]. This approach not only optimizes clinical outcomes but also enhances patient satisfaction, as treatments align more closely with patient expectations.
MCID plays a critical role in patient counseling by providing patients with clear, understandable information about what they can expect from different treatment options[32,33]. In cancer care, discussing the MCID associated with different chemotherapy regimens helps patients make informed decisions based on how likely the treatments are to yield meaningful improvements in symptoms or quality of life. This is especially important in conditions where treatment involves significant side effects or where the choice between treatment options involves complex trade-offs regarding efficacy, side effects, and impact on quality of life. MCID can influence the development of clinical guidelines and healthcare policies by identifying which interventions offer meaningful benefits to patients[5,34,35]. This ensures that healthcare resources are allocated effectively, promoting interventions that provide the greatest value to patients. For instance, the use of MCID in large-scale clinical trials can help policy makers decide which treatments should be recommended or reimbursed based on their capacity to achieve clinically meaningful outcomes[33].
CHALLENGES AND CONTROVERSIES SURROUNDING MCID
MCID is an invaluable concept in clinical research and practice, aimed at bridging the gap between statistical significance and clinical relevance. However, its application is fraught with challenges and controversies that complicate its use in clinical settings (Table 2). These issues range from methodological difficulties in its calculation to problems in its interpretation and application, sparking ongoing debates among healthcare professionals and researchers.
Table 2 Challenges and controversies in minimal clinically important difference implementation.
Challenge category
Specific issue
Impact on MCID application
Proposed solution
Methodological
Variability in calculation methods
Leads to inconsistent MCID values
Standardize calculation methods and develop guidelines
Interpretational
Misinterpretation of what changes are clinically important
Can result in inappropriate treatment decisions
Educate clinicians on nuanced interpretation of MCID values
Demographic influence
Variations in MCID across different patient demographics
Difficulty applying MCID universally
Conduct cross-cultural studies to validate MCID in diverse populations
Clinical application
Generic use in individual patient management
May overlook individual patient needs
Tailor MCID application by incorporating individual patient preferences
Research and policy
Lack of standardized reporting in research
Hampers the comparability of studies
Implement uniform reporting standards for MCID findings
Patient involvement
Limited patient input in setting MCID thresholds
May not reflect true patient priorities
Increase patient involvement through advisory panels and participatory research
Methodological issues
One of the principal challenges in calculating MCID is the variability of methods used to determine it, which can lead to significantly different MCID values for the same condition across different studies. There are primarily two methods used: Anchor-based and distribution-based approaches. Anchor-based methods rely on an external standard or 'anchor', which is usually a patient-reported outcome that the patient considers important. In contrast, distribution-based methods use statistical calculations to determine what constitutes a meaningful change based on the distribution of data[16]. Each method has its strengths and weaknesses, and the choice between them can significantly influence the MCID calculated. The variability in MCID across different patient demographics poses another significant challenge. Factors such as age, gender, cultural background, and baseline severity of disease can affect patients' perceptions of what constitutes a meaningful improvement in their condition[17]. This demographic influence means that MCID calculated for one population may not be applicable to another, complicating the use of MCID in multi-national clinical trials or in settings with diverse patient populations.
Interpretation problems
Interpreting MCID values correctly is crucial, yet it can be complex and fraught with potential misapplications. One common issue is the assumption that any change above the MCID threshold is clinically important, which might not always be the case. For instance, a small change might surpass the MCID threshold but still be insufficient for making a clinically relevant decision, especially in treatments requiring a high threshold for change due to severe potential side effects[17]. Moreover, the risk of misapplying MCID in clinical settings is significant, particularly when these values are used to make broad treatment decisions for individual patients without considering personal preferences and individual differences. For example, using a generic MCID for treatment decisions in chronic pain management may ignore individual patient responses to pain, which can vary widely as shown in Figure 1 where the MCID of numerical pain rating scale for an intervention is noted to be 2. However, the patient might not get their disability or the symptoms relieved since their thresholds may vary from person to person. Hence, MCID might not guarantee symptomatic relief in every patient for a given intervention.
Figure 1 Interpretation of minimal clinically important difference of numerical pain rating scale for an intervention.
MCID: Minimal clinically important difference.
IMPROVING MCID UTILITY: RECOMMENDATIONS AND FUTURE DIRECTIONS
Standardization efforts
One of the foremost steps in enhancing the utility of MCID is the standardization of its calculation and reporting methods. This would not only improve the reproducibility of results but also ensure comparability across studies, facilitating better clinical decision-making and policy formulation. To achieve this, the following strategies could be implemented:
Development of guidelines: Professional bodies and research groups should collaborate to develop consensus-based guidelines that outline standardized procedures for calculating MCID[34,36,37]. These guidelines should recommend specific methods tailored to different conditions and patient populations, taking into account the disease severity, treatment type, and expected outcomes.
Uniform reporting standards: Alongside calculation guidelines, there should be a standardized reporting framework that specifies how MCID findings should be presented in research publications. This framework should include details on the statistical methods used, the anchor measures employed (if any), and the demographic characteristics of the study population[38-40]. This would enhance transparency and allow for easier comparison and meta-analysis of MCID data across different studies.
Cross-disciplinary validation: Encourage cross-disciplinary studies to validate MCID thresholds across different healthcare settings and specialties[41]. This would help in understanding how MCID varies by context and in developing more universal application models that are adaptable to various clinical and cultural environments.
Integrating patient input
Incorporating patient feedback into the setting of MCID thresholds is essential for ensuring that these thresholds truly reflect outcomes that matter to patients. Patient involvement can be enhanced through the following approaches:
Patient-centered research designs: Utilize patient-centered research designs such as participatory action research where patients actively participate in the study design, implementation, and analysis processes[42-44]. This inclusion helps ensure that the MCID derived is genuinely reflective of patient perspectives and needs.
Use of patient advisory panels: Establish patient advisory panels that can provide ongoing feedback on the relevance and applicability of MCID thresholds in clinical trials and practice[45,46]. These panels should be diverse, representing a range of demographics and patient experiences to capture a wide array of perspectives.
Routine patient surveys and interviews: Implement routine surveys and structured interviews to gather qualitative data from patients regarding their perceptions of meaningful change post-treatment[47,48]. This data can be instrumental in setting or adjusting MCID thresholds in a manner that aligns with patient priorities and expectations.
Future research
To refine the application of MCID and increase its relevance and impact, several areas of research should be prioritized:
Methodological refinement: Further research is needed to refine MCID calculation methods, especially in exploring hybrid models that combine both anchor-based and distribution-based approaches. Research should also explore the impact of different statistical techniques and the robustness of MCID under various analytical conditions.
Longitudinal studies: Conduct longitudinal studies to assess how MCID thresholds may change over time with disease progression or improvement. Understanding these dynamics can help in tailoring treatments more effectively to patient needs at different stages of a condition.
Impact of MCID on clinical outcomes: Investigate how the use of MCID in clinical decision-making impacts patient outcomes over the long term. This includes studying patient satisfaction, adherence to treatment, and overall quality of life, providing a holistic view of the benefits and limitations of MCID-focused approaches.
Global health contexts: Expand research to include diverse populations, especially from low- and middle-income countries, to determine how socio-economic and cultural factors influence MCID perceptions. This is crucial for the global applicability of MCID thresholds in public health and clinical settings.
By focusing on these areas, the future of MCID application can be shaped to provide more patient-centered, culturally sensitive, and clinically relevant outcomes. The evolution of MCID from a theoretical concept to a standard tool in clinical and research settings underscores its potential to transform patient care by ensuring that medical interventions lead to meaningful, patient-perceived improvements. This progress, however, depends on continued efforts to refine, standardize, and adapt MCID methodologies to meet the complex and varied needs of patients worldwide.
To enhance the utility of MCID, we propose the following prioritized recommendations:
High-impact, short-term goals: Standardization of MCID calculation methods; integration of patient input; methodological refinement.
Long-term, high-impact goals: Impact of MCID on clinical outcomes; global health contexts.
By focusing on these prioritized areas, we can shape the future of MCID application to provide more patient-centered, culturally sensitive, and clinically relevant outcomes. The evolution of MCID from a theoretical concept to a standard tool in clinical and research settings underscores its potential to transform patient care by ensuring that medical interventions lead to meaningful, patient-perceived improvements.
CONCLUSION
MCID is an essential metric for aligning clinical outcomes with patient-centered care, offering a nuanced balance between statistical significance and clinical relevance. To enhance the utility of MCID, it is recommended that standardized guidelines for its calculation and reporting be established. This standardization should be complemented by incorporating patient input directly into the determination of MCID thresholds, ensuring that they reflect changes in treatment outcomes that are meaningful to patients. Furthermore, the continued evolution of MCID application requires rigorous methodological refinement and the integration of diverse patient perspectives from global populations. These steps will not only promote more personalized and effective healthcare but also ensure that interventions provide tangible benefits that are valued by patients. Such strategic advancements will solidify the role of MCID in fostering healthcare practices that are both scientifically sound and deeply attuned to patient needs and experiences.
Footnotes
Provenance and peer review: Invited article; Externally peer reviewed.
Peer-review model: Single blind
Specialty type: Orthopedics
Country of origin: India
Peer-review report’s classification
Scientific Quality: Grade B
Novelty: Grade B
Creativity or Innovation: Grade C
Scientific Significance: Grade B
P-Reviewer: Liaqat N S-Editor: Liu JH L-Editor: A P-Editor: Zhang L
Prasad M. Importance of minimal clinically important difference in medical research and guideline development.JEFI. 2024;2:01-04.
[PubMed] [DOI][Cited in This Article: ]
Mishra B, Sudheer P, Agarwal A, Srivastava MVP, Nilima, Vishnu VY. Minimal Clinically Important Difference (MCID) in Patient-Reported Outcome Measures for Neurological Conditions: Review of Concept and Methods.Ann Indian Acad Neurol. 2023;26:334-343.
[PubMed] [DOI][Cited in This Article: ][Reference Citation Analysis (0)]
Molino J, Harrington J, Racine-Avila J, Aaron R. Deconstructing the Minimum Clinically Important Difference (MCID).Orthop Res Rev. 2022;14:35-42.
[PubMed] [DOI][Cited in This Article: ][Reference Citation Analysis (0)]
Wu X, Liu J, Tanadini LG, Lammertse DP, Blight AR, Kramer JL, Scivoletto G, Jones L, Kirshblum S, Abel R, Fawcett J, Field-Fote E, Guest J, Levinson B, Maier D, Tansey K, Weidner N, Tetzlaff WG, Hothorn T, Curt A, Steeves JD. Challenges for defining minimal clinically important difference (MCID) after spinal cord injury.Spinal Cord. 2015;53:84-91.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 59][Cited by in F6Publishing: 59][Article Influence: 5.9][Reference Citation Analysis (0)]
Iyer LV, Haley SM, Watkins MP, Dumas HM. Establishing minimal clinically important differences for scores on the pediatric evaluation of disability inventory for inpatient rehabilitation.Phys Ther. 2003;83:888-898.
[PubMed] [DOI][Cited in This Article: ]
Lang CE, Holleran CL, Strube MJ, Ellis TD, Newman CA, Fahey M, DeAngelis TR, Nordahl TJ, Reisman DS, Earhart GM, Lohse KR, Bland MD. Improvement in the Capacity for Activity Versus Improvement in Performance of Activity in Daily Life During Outpatient Rehabilitation.J Neurol Phys Ther. 2023;47:16-25.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 29][Cited by in F6Publishing: 16][Article Influence: 16.0][Reference Citation Analysis (0)]
Palmer M, Sutherland J, Barnard S, Wynne A, Rezel E, Doel A, Grigsby-Duffy L, Edwards S, Russell S, Hotopf E, Perel P, Free C. The effectiveness of smoking cessation, physical activity/diet and alcohol reduction interventions delivered by mobile phones for the prevention of non-communicable diseases: A systematic review of randomised controlled trials.PLoS One. 2018;13:e0189801.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 60][Cited by in F6Publishing: 66][Article Influence: 11.0][Reference Citation Analysis (0)]
Magouliotis DE, Bareka M, Rad AA, Christodoulidis G, Athanasiou T. Demystifying the Value of Minimal Clinically Important Difference in the Cardiothoracic Surgery Context.Life (Basel). 2023;13.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 1][Reference Citation Analysis (0)]
Monti MM, Spivak NM, Edlow BL, Bodien YG. What is a minimal clinically important difference for clinical trials in patients with disorders of consciousness? a novel probabilistic approach.PLoS One. 2023;18:e0290290.
[PubMed] [DOI][Cited in This Article: ][Reference Citation Analysis (0)]
Cummings J. Meaningful benefit and minimal clinically important difference (MCID) in Alzheimer's disease: Open peer commentary.Alzheimers Dement (N Y). 2023;9:e12411.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 3][Reference Citation Analysis (0)]
Mishra B, Sudheer P, Rajan R, Agarwal A, Srivastava MVP, Nilima N, Vishnu VY. Bridging the gap between statistical significance and clinical relevance: A systematic review of minimum clinically important difference (MCID) thresholds of scales reported in movement disorders research.Heliyon. 2024;10:e26479.
[PubMed] [DOI][Cited in This Article: ][Reference Citation Analysis (0)]
Olsen MF, Bjerre E, Hansen MD, Hilden J, Landler NE, Tendal B, Hróbjartsson A. Pain relief that matters to patients: systematic review of empirical studies assessing the minimum clinically important difference in acute pain.BMC Med. 2017;15:35.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 193][Cited by in F6Publishing: 265][Article Influence: 37.9][Reference Citation Analysis (0)]
Brennan J, Poon MTC, Christopher E, Fulton O, Porteous C, Brennan PM. Reporting of PPI and the MCID in phase III/IV randomised controlled trials-a systematic review.Trials. 2023;24:370.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 2][Reference Citation Analysis (0)]
Mesa R, Gupta V, Mascarenhas J, Hobbs G, Kiladjian J, Coltro G, Bagnardi V, Oriecuia C, Kann L, Colak G, Harrison CN, Dey D. Assessment of Minimal Clinically Important Difference in Patient-Reported Myelofibrosis-Associated Symptoms Using an Anchor-Based Analysis Based on MANIFEST Arm 3 Data.Blood. 2023;142:3195-3195.
[PubMed] [DOI][Cited in This Article: ]